SK Bioscience will invest 150 billion won to build a new facility for production of messenger ribonucleic acid (mRNA) vaccines.SK Bioscience signed a memorandum of understanding (MOU) with North Gyeongsang Province and Andong City on expansion of its production facilities on June 21. The company’s v
Korea is seeking to produce the world's third mRNA COVID-19 vaccine from CureVac, a German biopharmaceutical company that develops therapies based on messenger RNA.Korean President Moon Jae-in and CureVac CEO Franz-Werner Haas agreed to form a new vaccine partnership during a meeting through a v
The nanoparticle technology applied to SK Bioscience's COVID-19 vaccine GBP510, which is under development, is drawing attention. Nanoparticles applied to GBP510 were jointly developed by researchers at SK Bioscience and the University of Washington. The university’s nanoparticle technology is k
POSCO International announced on June 9 that it has signed a business agreement with Biot Korea, a startup specializing in medical robots, to move into overseas medical robot markets.The two companies will jointly participate in the 2021 BIO KOREA Exhibition, which runs from June 9-11.They will also
JW Pharmaceutical announced on June 9 that an antibiotic manufactured using ertapenem of its own development has been launched in the United States.Ertapenem is one of the carbapenem antibiotics, which also include imipenem, meropenem, and doripenem. Carbapenems are a class of highly effective antib
An increasing number of South Korean companies are entering the field of mRNA vaccine development and manufacturing.For instance, Samsung Biologics, which recently signed a contract manufacturing agreement with Moderna, is planning to expand its facilities for the purpose of mRNA vaccine ingredient
Ildong Pharmaceutical has acquired a patent on a composition that can improve dyslipidemia by utilizing live and heat-killed probiotic strains.While conventional medicines treat hyperlipidemia by inhibiting cholesterol synthesis in the body, the company has developed a composition that can discharge
Samsung Biologics as well as SK Bioscience signed a contract manufacturing agreement for COVID-19 vaccine supply. In addition, traditional pharmaceutical companies are entering this field one after another.SK Bioscience and Samsung Biologics concluded such agreements with Novavax and Moderna in Augu
The author is an analyst of NH Investment & Securities. He can be reached at jaemin.ahn@nhqv.com. -- Ed. 1. 5G subscriber-led wireless revenue growth to fuel OP expansionTelcos entering earnings upcycleHelped by a faster-than-expected increase in 5G penetration, telcos look to have entered a phase o
Masayoshi Son, chairman of Japan's SoftBank Group, has picked Yanolja as a Korean venture company that can become the next Coupang. Son is expected to invest two trillion won to grow Yanolja into a global accommodation and travel platform and directly list it in the U.S. stock market.Son’s Visio
Dong-A ST, a pharmaceutical affiliate of Dong-A Socio Group, has drastically revamped its R&D (R&D) organization. It created a biotech lab and introduced a team system to its new drug lab to speed up the pace of research."The reform is intended to expand the company’s research domain from synthetic
South Korean enterprises announced their 44 trillion won investment plan at the Korea-U.S. Business Roundtable the U.S. Department of Commerce hosted on May 21. Under the circumstances, China’s response is drawing attention.The closer U.S.-South Korea cooperation in the semiconductor, electric vehic
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics, a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, announced on May 23 a manufacturing services and supply agreement in which
The South Korean government recently had a meeting with 10 or so biotech companies in order to discuss mRNA vaccine R&D and manufacturing.At present, COVID-19 vaccines of this type are supplied by Pfizer and Moderna and South Korean companies are yet to conduct clinical trials with this type of COVI
The Export-Import Bank of Korea announced on May 13 that it has signed a business agreement with the Korea Health Industry Development Institute (KHIDI) to strengthen cooperation in supporting Korean companies’ expansion into overseas markets in the healthcare and medical sector.The state-run bank m
The Blue House and the Ministry of Trade, Industry and Energy are drawing up a list of entrepreneurs to visit the United States in relation to the May 21 KORUS summit.SK Group chairman Chey Tae-won is expected to discuss investment in the electric vehicle (EV) battery industry and cooperation in the
U.S. bio-tech company Roivant Sciences, which received an equity investment from SK Group, was valued at US$7.3 billion ahead of its listing on the New York Stock Exchange. The company’s value is similar to that of Moderna Therapeutics, which set the record for the biggest biotech IPO at US$7.5 bill
U.S. pharmaceutical ingredient manufacturer AMPAC Fine Chemicals is planning to expand its facilities in the United States by investing up to US$25 million. The idea is to enhance its competitiveness in the field of contract development and manufacturing by strengthening its R&D functions and increa
Concerns are mounting over technology leaks from Korea's key industries including semiconductor and secondary battery manufacturing. This is because China is increasingly targeting South Korea while the United States and other countries are increasing their degrees of industrial protection.Accor
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on May 3 that South Korean pharmaceutical and biotech companies’ technology exports added up to 4,336.6 billion won in the first quarter of this year, when a total of six companies in the industry concluded such contracts.Th